• Medicare released the final rules governing payments for dialysis services for beneficiaries with end-stage renal disease.

• An FDA advisory panel rejected the agency's proposed class-wide REMS plan for extended-release and long-acting opioids, arguing it was too weak and lacked teeth.

• Biogen Idec Inc.'s head of drug safety took the FDA to task over burdensome, unhelpful items in REMS.